Cargando…

Recent Advances of Ocular Drug Delivery Systems: Prominence of Ocular Implants for Chronic Eye Diseases

Chronic ocular diseases can seriously impact the eyes and could potentially result in blindness or serious vision loss. According to the most recent data from the WHO, there are more than 2 billion visually impaired people in the world. Therefore, it is pivotal to develop more sophisticated, long-ac...

Descripción completa

Detalles Bibliográficos
Autores principales: Mostafa, Mahmoud, Al Fatease, Adel, Alany, Raid G., Abdelkader, Hamdy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10302848/
https://www.ncbi.nlm.nih.gov/pubmed/37376194
http://dx.doi.org/10.3390/pharmaceutics15061746
_version_ 1785065139778617344
author Mostafa, Mahmoud
Al Fatease, Adel
Alany, Raid G.
Abdelkader, Hamdy
author_facet Mostafa, Mahmoud
Al Fatease, Adel
Alany, Raid G.
Abdelkader, Hamdy
author_sort Mostafa, Mahmoud
collection PubMed
description Chronic ocular diseases can seriously impact the eyes and could potentially result in blindness or serious vision loss. According to the most recent data from the WHO, there are more than 2 billion visually impaired people in the world. Therefore, it is pivotal to develop more sophisticated, long-acting drug delivery systems/devices to treat chronic eye conditions. This review covers several drug delivery nanocarriers that can control chronic eye disorders non-invasively. However, most of the developed nanocarriers are still in preclinical or clinical stages. Long-acting drug delivery systems, such as inserts and implants, constitute the majority of the clinically used methods for the treatment of chronic eye diseases due to their steady state release, persistent therapeutic activity, and ability to bypass most ocular barriers. However, implants are considered invasive drug delivery technologies, especially those that are nonbiodegradable. Furthermore, in vitro characterization approaches, although useful, are limited in mimicking or truly representing the in vivo environment. This review focuses on long-acting drug delivery systems (LADDS), particularly implantable drug delivery systems (IDDS), their formulation, methods of characterization, and clinical application for the treatment of eye diseases.
format Online
Article
Text
id pubmed-10302848
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103028482023-06-29 Recent Advances of Ocular Drug Delivery Systems: Prominence of Ocular Implants for Chronic Eye Diseases Mostafa, Mahmoud Al Fatease, Adel Alany, Raid G. Abdelkader, Hamdy Pharmaceutics Review Chronic ocular diseases can seriously impact the eyes and could potentially result in blindness or serious vision loss. According to the most recent data from the WHO, there are more than 2 billion visually impaired people in the world. Therefore, it is pivotal to develop more sophisticated, long-acting drug delivery systems/devices to treat chronic eye conditions. This review covers several drug delivery nanocarriers that can control chronic eye disorders non-invasively. However, most of the developed nanocarriers are still in preclinical or clinical stages. Long-acting drug delivery systems, such as inserts and implants, constitute the majority of the clinically used methods for the treatment of chronic eye diseases due to their steady state release, persistent therapeutic activity, and ability to bypass most ocular barriers. However, implants are considered invasive drug delivery technologies, especially those that are nonbiodegradable. Furthermore, in vitro characterization approaches, although useful, are limited in mimicking or truly representing the in vivo environment. This review focuses on long-acting drug delivery systems (LADDS), particularly implantable drug delivery systems (IDDS), their formulation, methods of characterization, and clinical application for the treatment of eye diseases. MDPI 2023-06-15 /pmc/articles/PMC10302848/ /pubmed/37376194 http://dx.doi.org/10.3390/pharmaceutics15061746 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Mostafa, Mahmoud
Al Fatease, Adel
Alany, Raid G.
Abdelkader, Hamdy
Recent Advances of Ocular Drug Delivery Systems: Prominence of Ocular Implants for Chronic Eye Diseases
title Recent Advances of Ocular Drug Delivery Systems: Prominence of Ocular Implants for Chronic Eye Diseases
title_full Recent Advances of Ocular Drug Delivery Systems: Prominence of Ocular Implants for Chronic Eye Diseases
title_fullStr Recent Advances of Ocular Drug Delivery Systems: Prominence of Ocular Implants for Chronic Eye Diseases
title_full_unstemmed Recent Advances of Ocular Drug Delivery Systems: Prominence of Ocular Implants for Chronic Eye Diseases
title_short Recent Advances of Ocular Drug Delivery Systems: Prominence of Ocular Implants for Chronic Eye Diseases
title_sort recent advances of ocular drug delivery systems: prominence of ocular implants for chronic eye diseases
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10302848/
https://www.ncbi.nlm.nih.gov/pubmed/37376194
http://dx.doi.org/10.3390/pharmaceutics15061746
work_keys_str_mv AT mostafamahmoud recentadvancesofoculardrugdeliverysystemsprominenceofocularimplantsforchroniceyediseases
AT alfateaseadel recentadvancesofoculardrugdeliverysystemsprominenceofocularimplantsforchroniceyediseases
AT alanyraidg recentadvancesofoculardrugdeliverysystemsprominenceofocularimplantsforchroniceyediseases
AT abdelkaderhamdy recentadvancesofoculardrugdeliverysystemsprominenceofocularimplantsforchroniceyediseases